{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High+Grade&page=15", "query": { "condition": "High Grade", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 165, "total_pages": 17, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High+Grade&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High+Grade&page=14&page_size=10" }, "source": "local", "last_synced_at": "2026-10-17T14:36:05.090Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02834013", "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acinar Cell Carcinoma", "Adenoid Cystic Carcinoma", "Adrenal Cortical Carcinoma", "Adrenal Gland Pheochromocytoma", "Anal Canal Neuroendocrine Carcinoma", "Anal Canal Undifferentiated Carcinoma", "Angiosarcoma", "Apocrine Neoplasm", "Appendix Mucinous Adenocarcinoma", "Bartholin Gland Transitional Cell Carcinoma", "Basal Cell Carcinoma", "Bladder Adenocarcinoma", "Breast Metaplastic Carcinoma", "Cervical Adenocarcinoma", "Cholangiocarcinoma", "Chordoma", "Colorectal Squamous Cell Carcinoma", "Desmoid Fibromatosis", "Endometrial Transitional Cell Carcinoma", "Endometrioid Adenocarcinoma", "Esophageal Neuroendocrine Carcinoma", "Esophageal Undifferentiated Carcinoma", "Extrahepatic Bile Duct Carcinoma", "Extramammary Paget Disease", "Fallopian Tube Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fibromyxoid Tumor", "Gallbladder Carcinoma", "Gastric Neuroendocrine Carcinoma", "Gastric Squamous Cell Carcinoma", "Gastric Undifferentiated Carcinoma", "Gastrointestinal Stromal Tumor", "Gestational Trophoblastic Tumor", "Giant Cell Carcinoma", "Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type", "Intestinal Neuroendocrine Carcinoma", "Intrahepatic Cholangiocarcinoma", "Lung Neuroendocrine Tumor", "Lung Sarcomatoid Carcinoma", "Major Salivary Gland Carcinoma", "Malignant Neoplasm of Unknown Primary", "Malignant Odontogenic Neoplasm", "Malignant Peripheral Nerve Sheath Tumor", "Malignant Solid Neoplasm", "Malignant Testicular Sex Cord-Stromal Tumor", "Metastatic Pituitary Neuroendocrine Tumor", "Minimally Invasive Lung Adenocarcinoma", "Mixed Mesodermal (Mullerian) Tumor", "Mucinous Adenocarcinoma", "Mucinous Cystadenocarcinoma", "Nasal Cavity Adenocarcinoma", "Nasal Cavity Carcinoma", "Nasopharyngeal Carcinoma", "Nasopharyngeal Low Grade Papillary Adenocarcinoma", "Nasopharyngeal Undifferentiated Carcinoma", "Oral Cavity Carcinoma", "Oropharyngeal Undifferentiated Carcinoma", "Ovarian Adenocarcinoma", "Ovarian Germ Cell Tumor", "Ovarian Mucinous Adenocarcinoma", "Ovarian Squamous Cell Carcinoma", "Ovarian Transitional Cell Carcinoma", "PEComa", "Pancreatic Acinar Cell Carcinoma", "Pancreatic Neuroendocrine Carcinoma", "Paraganglioma", "Paranasal Sinus Adenocarcinoma", "Paranasal Sinus Carcinoma", "Parathyroid Gland Carcinoma", "Penile Squamous Cell Carcinoma", "Peritoneal Mesothelial Neoplasm", "Placental Choriocarcinoma", "Primary Peritoneal High Grade Serous Adenocarcinoma", "Pseudomyxoma Peritonei", "Rare Disorder", "Scrotal Squamous Cell Carcinoma", "Seminal Vesicle Adenocarcinoma", "Seminoma", "Serous Cystadenocarcinoma", "Small Intestinal Adenocarcinoma", "Small Intestinal Squamous Cell Carcinoma", "Spindle Cell Neoplasm", "Teratoma With Somatic-Type Malignancy", "Testicular Non-Seminomatous Germ Cell Tumor", "Thyroid Gland Carcinoma", "Tracheal Carcinoma", "Transitional Cell Carcinoma", "Ureter Adenocarcinoma", "Ureter Squamous Cell Carcinoma", "Urethral Adenocarcinoma", "Urethral Squamous Cell Carcinoma", "Vaginal Adenocarcinoma", "Vaginal Squamous Cell Carcinoma, Not Otherwise Specified", "Vulvar Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 798, "start_date": "2017-01-30", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-09-25T15:31:29.073Z", "location_count": 1006, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 620 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02834013" }, { "nct_id": "NCT00840047", "title": "Methionine PET/CT Studies In Patients With Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain Stem Glioma", "Brain Tumors and/or Solid Tumors Including", "Craniopharyngioma", "Ependymoma", "Ewing Sarcoma", "High Grade CNS Tumors", "Hodgkin Lymphoma", "Low Grade CNS Tumors", "Medulloblastoma", "Neuroblastoma", "Non Hodgkin Lymphoma", "Osteosarcoma", "Other", "Rhabdomyosarcoma" ], "interventions": [ { "name": "Methionine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 503, "start_date": "2009-07-20", "completion_date": "2027-07-27", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-16T05:36:34.334Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00840047" }, { "nct_id": "NCT04454450", "title": "Using Advanced Imaging Studies to Develop a Profile of High-grade Serous Ovarian Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "High Grade Ovarian Serous", "Ovarian Cancer" ], "interventions": [ { "name": "Contrast enhanced CT", "type": "DIAGNOSTIC_TEST" }, { "name": "PET/MRI", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 10, "start_date": "2020-06-22", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-10-15T02:45:06.528Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04454450" }, { "nct_id": "NCT03449108", "title": "LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bone Sarcoma", "Dedifferentiated Chondrosarcoma", "Giant Cell Tumor of Bone", "Malignancy in Giant Cell Tumor of Bone", "Malignant Solid Neoplasm", "Ovarian Carcinosarcoma", "Platinum-Resistant Ovarian Carcinoma", "Poorly Differentiated Thyroid Gland Carcinoma", "Recurrent Osteosarcoma", "Recurrent Ovarian Carcinoma", "Refractory Osteosarcoma", "Soft Tissue Sarcoma", "Thyroid Gland Anaplastic Carcinoma", "Thyroid Gland Squamous Cell Carcinoma", "Triple Negative Breast Cancer", "Undifferentiated High Grade Pleomorphic Sarcoma of Bone" ], "interventions": [ { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "Autologous Tumor Infiltrating Lymphocytes LN-145", "type": "BIOLOGICAL" }, { "name": "Autologous Tumor Infiltrating Lymphocytes LN-145-S1", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "16 Years to 70 Years" }, "enrollment_count": 30, "start_date": "2018-04-27", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-14T06:50:03.457Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03449108" }, { "nct_id": "NCT03038672", "title": "Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "ALK-Positive Large B-Cell Lymphoma", "Diffuse Large B-Cell Lymphoma Activated B-Cell Type", "Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation", "Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type", "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "EBV-Positive Mucocutaneous Ulcer", "HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements", "High Grade B-Cell Lymphoma, Not Otherwise Specified", "Intravascular Large B-Cell Lymphoma", "Large B-Cell Lymphoma With 11q Aberration", "Large B-Cell Lymphoma With IRF4 Rearrangement", "Plasmablastic Lymphoma", "Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System", "Primary Effusion Lymphoma", "Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Burkitt Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Gray-Zone Lymphoma", "Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Recurrent Lymphomatoid Granulomatosis", "Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type", "Recurrent Primary Mediastinal Large B-Cell Lymphoma", "Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma", "Refractory B-Cell Non-Hodgkin Lymphoma", "Refractory Burkitt Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Gray-Zone Lymphoma", "Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type", "Refractory Primary Mediastinal Large B-Cell Lymphoma", "Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Varlilumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2018-12-21", "completion_date": "2026-10-24", "has_results": true, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-10-15T10:34:25.245Z", "location_count": 33, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 24 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03038672" }, { "nct_id": "NCT05507541", "title": "TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent ALK Positive Large B-Cell Lymphoma", "Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation", "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Recurrent Grade 3b Follicular Lymphoma", "Recurrent Gray Zone Lymphoma", "Recurrent High Grade B-Cell Lymphoma", "Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified", "Recurrent Intravascular Large B-Cell Lymphoma", "Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type", "Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma", "Refractory ALK Positive Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation", "Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Refractory Grade 3b Follicular Lymphoma", "Refractory High Grade B-Cell Lymphoma", "Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified", "Refractory Intravascular Large B-Cell Lymphoma", "Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type", "Refractory Primary Mediastinal Large B-Cell Lymphoma", "Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Maplirpacept", "type": "DRUG" }, { "name": "Ontorpacept", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2023-04-19", "completion_date": "2027-07-30", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-08-16T04:15:56.232Z", "location_count": 2, "location_summary": "Iowa City, Iowa • Rochester, Minnesota", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05507541" }, { "nct_id": "NCT05645146", "title": "Enhancing Long-Term Smoking Abstinence Among Cervical Cancer Survivors (Project ACCESS)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cervical Cancer", "High Grade Cervical Dysplasia", "Smoking Cessation" ], "interventions": [ { "name": "Motivation and Problem Solving (MAPS) intervention", "type": "BEHAVIORAL" }, { "name": "Nicotine Lozenge", "type": "DRUG" }, { "name": "Nicotine patch", "type": "DRUG" }, { "name": "Smoking Cessation treatment delivered by Tobacco Free Florida Quitline", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL", "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 360, "start_date": "2022-11-29", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-10-14T12:46:18.592Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05645146" }, { "nct_id": "NCT03605550", "title": "A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Intrinsic Pontine Glioma", "High Grade Glioma" ], "interventions": [ { "name": "PTC596", "type": "DRUG" }, { "name": "Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Nationwide Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 64, "start_date": "2018-08-01", "completion_date": "2029-03-01", "has_results": false, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-10-03T00:22:24.276Z", "location_count": 10, "location_summary": "Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 7 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03605550" }, { "nct_id": "NCT04802174", "title": "Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "High Grade Neuroendocrine Cancers", "SCLC", "Small Cell Cancer" ], "interventions": [ { "name": "Berzosertib", "type": "DRUG" }, { "name": "Lurbinectedin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2021-06-01", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2026-03-17", "last_synced_at": "2026-10-17T14:36:05.090Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04802174" }, { "nct_id": "NCT04420975", "title": "Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leiomyosarcoma", "Malignant Peripheral Nerve Sheath Tumor", "Myxofibrosarcoma", "Pleomorphic Rhabdomyosarcoma", "Resectable Dedifferentiated Liposarcoma", "Resectable Soft Tissue Sarcoma", "Resectable Undifferentiated Pleomorphic Sarcoma", "Soft Tissue Fibrosarcoma", "Spindle Cell Sarcoma", "Stage I Retroperitoneal Sarcoma AJCC (American Joint Committee on Cancer) v8", "Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8", "Stage IA Retroperitoneal Sarcoma AJCC v8", "Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8", "Stage IB Retroperitoneal Sarcoma AJCC v8", "Stage IB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8", "Stage II Retroperitoneal Sarcoma AJCC v8", "Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8", "Stage III Retroperitoneal Sarcoma AJCC v8", "Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8", "Stage IIIA Retroperitoneal Sarcoma AJCC v8", "Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8", "Stage IIIB Retroperitoneal Sarcoma AJCC v8", "Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8", "Storiform-Pleomorphic Malignant Fibrous Histiocytoma", "Synovial Sarcoma", "Undifferentiated High Grade Pleomorphic Sarcoma of Bone", "Undifferentiated Pleomorphic Sarcoma", "Undifferentiated Pleomorphic Sarcoma With Osteoclast-Like Giant Cells", "Undifferentiated Pleomorphic Sarcoma, Inflammatory Variant", "Undifferentiated Spindle Cell Sarcoma" ], "interventions": [ { "name": "Definitive Surgical Resection", "type": "PROCEDURE" }, { "name": "Nanoplexed Poly I:C BO-112", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "RADIATION" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2020-10-14", "completion_date": "2028-01-31", "has_results": false, "last_update_posted_date": "2026-03-10", "last_synced_at": "2026-10-14T08:54:04.424Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04420975" } ] }